The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research projects across the institution. “We are grateful for CPRIT’s […]
MD Anderson
Neoadjuvant Immunotherapy With Relatlimab And Nivolumab Is Safe And Effective In Stage Iii Melanoma
Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in […]
CPRIT awards $2.5 million to support MD Anderson cancer research
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas (CPRIT) to support cancer research projects across the institution. Four of the five grants awarded to MD Anderson today […]
MD Anderson receives CPRIT funding to expand access to cervical cancer screening and treatment in Texas
The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of cervical cancer prevention services to rural and medically underserved populations. While cervical […]
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2022-23 “Best Hospitals” rankings. The institution has been one of the nation’s top two hospitals for cancer care […]
Md Anderson And BostonGene Announce Strategic Alliance To Advance Personalized Cancer Diagnostics And Treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures. The alliance brings together BostonGene’s innovative computational platform and CLIA-certified and CAP-accredited high complexity molecular laboratory with […]
Md Anderson Celebrates World Cancer Research Day, Progress Made To End Cancer Through Research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship. World Cancer […]
MD Anderson Research Highlights: ESMO 2021 Special Edition
Key presentations to focus on novel cell therapies, antibody-drug conjugates and neoadjuvant immunotherapy The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. […]
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the […]
Metabolic Inhibitor Iacs-6274 Shows Early Antitumor Effects In Underserved Patients With Advanced Cancers
Drug developed by MD Anderson’s Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trial The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated […]